Thyrocare Technologies Share Price
Sector: Healthcare Facilities
1024.70 +40.30 (4.09%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
971.05
Today’s High
1027.75
52 Week Low
605.05
52 Week High
1072.45
1015.70 +30.60 (3.11%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
968.40
Today’s High
1027.40
52 Week Low
616.50
52 Week High
1073.20
Key Metrics
- Market Cap (In Cr) 5410.74
- Beta 0.8
- Div. Yield (%) 2.13
- P/B 9.55
- TTM P/E 39.38
- Peg Ratio -2.88
- Sector P/E 23.24
- D/E 0
- Open Price 977.5
- Prev Close 984.4
Thyrocare Technologies Analysis
Price Analysis
-
1 Week-1.16%
-
3 Months40.68%
-
6 Month-0.65%
-
YTD8.04%
-
1 Year48.86%
Risk Meter
- 44% Low risk
- 44% Moderate risk
- 44% Balanced Risk
- 44% High risk
- 44% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 1
- 1
- 1
- 0.00
- Buy
- 0.00
- 0.00
- 0.00
- 1
- Hold
- 0.00
- 0.00
- 0.00
- 0.00
- Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Strong Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Total
- 1
- 1
- 1
- 1
Thyrocare Technologies News
Q4 results today: LTIMindtree, Tata Consumer, Bajaj Housing to declare earnings
2 min read . 23 Apr 2025Hospital stocks rise as govt plans daycare cancer centers in district hospitals
2 min read . 01 Feb 2025Thyrocare CEO Arokiaswamy Velumani takes Ola ride after 5-star event
2 min read . 27 Jan 2025Stocks to Watch: HUL, SBI, Piramal Pharma, Sona BLW, Pidilite Ind, and more
2 min read . 24 Oct 2024Thyrocare Technologies Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 687.35
- Selling/ General/ Admin Expenses Total
- 126.77
- Depreciation/ Amortization
- 55.26
- Other Operating Expenses Total
- 179.14
- Total Operating Expense
- 552.25
- Operating Income
- 135.1
- Net Income Before Taxes
- 145.44
- Net Income
- 91.51
- Diluted Normalized EPS
- 17.08
- Period
- 2025
- Total Assets
- 692.75
- Total Liabilities
- 146
- Total Equity
- 546.75
- Tangible Book Valueper Share Common Eq
- 81.84
- Period
- 2025
- Cashfrom Operating Activities
- 191.32
- Cashfrom Investing Activities
- -52.52
- Cashfrom Financing Activities
- -130.42
- Net Changein Cash
- 8.38
- Period
- 2024
- Total Revenue
- 571.88
- Selling/ General/ Admin Expenses Total
- 262.28
- Depreciation/ Amortization
- 47.01
- Other Operating Expenses Total
- 0.13
- Total Operating Expense
- 480.18
- Operating Income
- 91.7
- Net Income Before Taxes
- 95.98
- Net Income
- 70.76
- Diluted Normalized EPS
- 13.47
- Period
- 2024
- Total Assets
- 643.88
- Total Liabilities
- 117.11
- Total Equity
- 526.77
- Tangible Book Valueper Share Common Eq
- 79.7
- Period
- 2024
- Cashfrom Operating Activities
- 167.63
- Cashfrom Investing Activities
- -91.28
- Cashfrom Financing Activities
- -84.81
- Net Changein Cash
- -8.46
- Period
- 2023
- Total Revenue
- 526.67
- Selling/ General/ Admin Expenses Total
- 238.71
- Depreciation/ Amortization
- 38.71
- Other Operating Expenses Total
- 0.42
- Total Operating Expense
- 444.48
- Operating Income
- 82.19
- Net Income Before Taxes
- 88.59
- Net Income
- 64.49
- Diluted Normalized EPS
- 12.25
- Period
- 2023
- Total Assets
- 632.72
- Total Liabilities
- 98.42
- Total Equity
- 534.3
- Tangible Book Valueper Share Common Eq
- 81.85
- Period
- 2023
- Cashfrom Operating Activities
- 129.31
- Cashfrom Investing Activities
- -38.99
- Cashfrom Financing Activities
- -86.18
- Net Changein Cash
- 4.14
- Period
- 2022
- Total Revenue
- 588.86
- Selling/ General/ Admin Expenses Total
- 177.31
- Depreciation/ Amortization
- 33.87
- Other Operating Expenses Total
- 4.17
- Total Operating Expense
- 385.71
- Operating Income
- 203.15
- Net Income Before Taxes
- 227.72
- Net Income
- 176.14
- Diluted Normalized EPS
- 32.93
- Period
- 2022
- Total Assets
- 607.66
- Total Liabilities
- 81.09
- Total Equity
- 526.57
- Tangible Book Valueper Share Common Eq
- 80.42
- Period
- 2022
- Cashfrom Operating Activities
- 113.41
- Cashfrom Investing Activities
- -23.57
- Cashfrom Financing Activities
- -89.41
- Net Changein Cash
- 0.43
- Period
- 2021
- Total Revenue
- 494.62
- Selling/ General/ Admin Expenses Total
- 155.61
- Depreciation/ Amortization
- 30.28
- Other Operating Expenses Total
- 2.51
- Total Operating Expense
- 351.86
- Operating Income
- 142.76
- Net Income Before Taxes
- 152.47
- Net Income
- 113.15
- Diluted Normalized EPS
- 20.55
- Period
- 2021
- Total Assets
- 545.8
- Total Liabilities
- 118.52
- Total Equity
- 427.28
- Tangible Book Valueper Share Common Eq
- 61.66
- Period
- 2021
- Cashfrom Operating Activities
- 116.04
- Cashfrom Investing Activities
- -50.23
- Cashfrom Financing Activities
- -61.57
- Net Changein Cash
- 4.24
- Period
- 2020
- Total Revenue
- 433.2
- Selling/ General/ Admin Expenses Total
- 138.6
- Depreciation/ Amortization
- 31.91
- Other Operating Expenses Total
- 3.52
- Total Operating Expense
- 299.17
- Operating Income
- 134.03
- Net Income Before Taxes
- 140.42
- Net Income
- 88.41
- Diluted Normalized EPS
- 17.49
- Period
- 2020
- Total Assets
- 469.33
- Total Liabilities
- 102.67
- Total Equity
- 366.66
- Tangible Book Valueper Share Common Eq
- 50.2
- Period
- 2020
- Cashfrom Operating Activities
- 167.63
- Cashfrom Investing Activities
- 0.95
- Cashfrom Financing Activities
- -164.78
- Net Changein Cash
- 3.8
- Period
- 2025-03-31
- Total Revenue
- 187.16
- Selling/ General/ Admin Expenses Total
- 33.47
- Depreciation/ Amortization
- 13.77
- Other Operating Expenses Total
- 46.52
- Total Operating Expense
- 143.23
- Operating Income
- 43.93
- Net Income Before Taxes
- 47.19
- Net Income
- 21.7
- Diluted Normalized EPS
- 4.16
- Period
- 2025-03-31
- Total Assets
- 692.75
- Total Liabilities
- 146
- Total Equity
- 546.75
- Tangible Book Valueper Share Common Eq
- 81.84
- Period
- 2025-03-31
- Cashfrom Operating Activities
- 191.32
- Cashfrom Investing Activities
- -52.52
- Cashfrom Financing Activities
- -130.42
- Net Changein Cash
- 8.38
- Period
- 2024-12-31
- Total Revenue
- 165.92
- Selling/ General/ Admin Expenses Total
- 35.09
- Depreciation/ Amortization
- 17.06
- Other Operating Expenses Total
- 43.94
- Total Operating Expense
- 141.25
- Operating Income
- 24.67
- Net Income Before Taxes
- 27.92
- Net Income
- 19.11
- Diluted Normalized EPS
- 3.56
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 177.36
- Selling/ General/ Admin Expenses Total
- 29.49
- Depreciation/ Amortization
- 13.07
- Other Operating Expenses Total
- 48.59
- Total Operating Expense
- 142.14
- Operating Income
- 35.22
- Net Income Before Taxes
- 36.78
- Net Income
- 26.68
- Diluted Normalized EPS
- 4.98
- Period
- 2024-09-30
- Total Assets
- 597.08
- Total Liabilities
- 108.92
- Total Equity
- 488.16
- Tangible Book Valueper Share Common Eq
- 71.79
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 89.08
- Cashfrom Investing Activities
- 69.82
- Cashfrom Financing Activities
- -122.46
- Net Changein Cash
- 36.44
- Period
- 2024-06-30
- Total Revenue
- 156.91
- Selling/ General/ Admin Expenses Total
- 28.72
- Depreciation/ Amortization
- 11.36
- Other Operating Expenses Total
- 40.09
- Total Operating Expense
- 125.63
- Operating Income
- 31.28
- Net Income Before Taxes
- 33.55
- Net Income
- 24.17
- Diluted Normalized EPS
- 4.51
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 154.25
- Selling/ General/ Admin Expenses Total
- 35.4
- Depreciation/ Amortization
- 13.06
- Other Operating Expenses Total
- 37.51
- Total Operating Expense
- 132.54
- Operating Income
- 21.71
- Net Income Before Taxes
- 22.91
- Net Income
- 17.78
- Diluted Normalized EPS
- 3.61
- Period
- 2024-03-31
- Total Assets
- 643.88
- Total Liabilities
- 117.11
- Total Equity
- 526.77
- Tangible Book Valueper Share Common Eq
- 79.7
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 167.63
- Cashfrom Investing Activities
- -91.28
- Cashfrom Financing Activities
- -84.81
- Net Changein Cash
- -8.46
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Thyrocare Technologies Technical
Moving Average
SMA
- 5 Day981.02
- 10 Day998.54
- 20 Day993.29
- 50 Day882.95
- 100 Day815.97
- 300 Day864.61
Thyrocare Technologies Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Healthcare Global Enterprises
- 548.05
- 3.3
- 0.61
- 636.8
- 345.25
- 7654.61
- Kovai Medical Cente And Hospital
- 5969.8
- -8.25
- -0.14
- 6400
- 4067.5
- 6531.28
- Thyrocare Technologies
- 1024.7
- 40.3
- 4.09
- 1072.45
- 605.05
- 5410.74
- Indraprastha Medical Corp
- 404.55
- -6.6
- -1.61
- 571.95
- 232.6
- 3712.62
- Artemis Medicare Services
- 254.3
- -6
- -2.31
- 348.3
- 171.8
- 3540.95
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Healthcare Global Enterprises
- 173.79
- 8.25
- -0.46
- -0.9
- Kovai Medical Cente And Hospital
- 31.66
- 6.09
- 19.69
- 13.18
- Thyrocare Technologies
- 58.27
- 9.65
- 20.87
- 17.91
- Indraprastha Medical Corp
- 24.05
- 6.49
- 22.89
- 8.31
- Artemis Medicare Services
- 49.95
- 4.36
- 9.91
- 5.88
Thyrocare Technologies Shareholding
Shareholding Pattern
*Promoter pledging: 71.06%
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 23-Apr-25
- Audited Results & Final Dividend
- 23-Jan-25
- Quarterly Results
- 23-Oct-24
- Quarterly Results
- 23-Jul-24
- Quarterly Results
- 14-May-24
- Audited Results & Final Dividend
- 01-Feb-24
- Quarterly Results
- 31-Oct-23
- Quarterly Results
- 01-Aug-23
- Quarterly Results
- 23-May-23
- Audited Results
- 07-Apr-23
- Interim Dividend
- Meeting Date
- Announced on
- Purpose
- 13-Jan-25
- 09-Dec-24
- POM
- 23-Aug-24
- 02-Aug-24
- AGM
- 10-Aug-23
- 14-Jul-23
- AGM
- 26-Jun-21
- 07-Jun-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 23-Apr-25
- -
- -
- 21
- 14-May-24
- 16-Aug-24
- 16-Aug-24
- 18
- 10-Apr-23
- 20-Apr-23
- 20-Apr-23
- 18
- 02-May-22
- 12-May-22
- 11-May-22
- 15
- 10-May-21
- -
- 17-Jun-21
- 15


